Clinical trials
Terminated Phase 1 Breast Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
175 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 1 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 3 |
| 2005 | 4 |
| 2006 | 3 |
| 2007 | 9 |
| 2008 | 6 |
| 2009 | 8 |
| 2010 | 14 |
| 2011 | 6 |
| 2012 | 5 |
| 2013 | 6 |
| 2014 | 8 |
| 2015 | 6 |
| 2016 | 14 |
| 2017 | 11 |
| 2018 | 8 |
| 2019 | 15 |
| 2020 | 12 |
| 2021 | 8 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 3 |
| 2025 | 3 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 175 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 17 |
| Pfizer | 9 |
| AbbVie | 3 |
| M.D. Anderson Cancer Center | 3 |
| Mayo Clinic | 3 |
| Novartis Pharmaceuticals | 3 |
| University of Utah | 3 |
| Accutar Biotechnology Inc | 2 |
| AstraZeneca | 2 |
| Case Comprehensive Cancer Center | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 175 |
| Carcinoma, Non-Small-Cell Lung | 25 |
| Ovarian Neoplasms | 24 |
| Neoplasms | 22 |
| Lung Neoplasms | 21 |
| Colorectal Neoplasms | 20 |
| Neoplasm Metastasis | 20 |
| Triple Negative Breast Neoplasms | 19 |
| Pancreatic Neoplasms | 18 |
| Melanoma | 17 |
Trials
Showing 1 to 25 of 175. Each trial links to its page on Pharma Observatory.
75 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.